0000000000406105

AUTHOR

Rossi M

showing 7 related works from this author

Nuovi ligandi per il trasportatore della Dopamina quali potenziali farmaci da utilizzare nella terapia da abuso di cocaina

2004

researchProduct

Sepsis at ICU admission does not decrease 30-day survival in very old patients : a post-hoc analysis of the VIP1 multinational cohort study

2020

AbstractBackgroundThe number of intensive care patients aged ≥ 80 years (Very old Intensive Care Patients; VIPs) is growing. VIPs have high mortality and morbidity and the benefits of ICU admission are frequently questioned. Sepsis incidence has risen in recent years and identification of outcomes is of considerable public importance. We aimed to determine whether VIPs admitted for sepsis had different outcomes than those admitted for other acute reasons and identify potential prognostic factors for 30-day survival.ResultsThis prospective study included VIPs with Sequential Organ Failure Assessment (SOFA) scores ≥ 2 acutely admitted to 307 ICUs in 21 European countries. Of 3869 acutely admi…

INTENSIVE-CARE-UNITSurvivalHSJ UCICritical Care and Intensive Care Medicinesurvival analysislaw.inventionsepsisSeverity of illne0302 clinical medicineLONG-TERM OUTCOMESoverlevingsanalyselawMedicine and Health SciencesEPIDEMIOLOGYIntensive care; Mortality; Outcome; Sepsis; Severity of illness; Survival; Very old030212 general & internal medicineProspective cohort studyELDERLY-PATIENTSOutcomeddc:617PATIENTS AGED 80lcsh:Medical emergencies. Critical care. Intensive care. First aidVery OldIntensive care unitSOFA scoremedicine.symptomCRITICALLY-ILL PATIENTSWITHDRAWALhormones hormone substitutes and hormone antagonistsmedicine.medical_specialtySepsiVery oldelderly patientsSeverity of illnessNOSepsis03 medical and health sciencessterfteSepsisInternal medicineIntensive careSeverity of illnessmedicineMortalityFRAILTYbusiness.industrySeptic shockResearchSEPTIC SHOCKOrgan dysfunctionIntensive Care030208 emergency & critical care medicinelcsh:RC86-88.9oudere patiëntenmedicine.diseaseIntensive carebusiness
researchProduct

Complexes of Tin(II) with 4-acyl-5-pyrazolonates: synthesis, spectroscopic and X-ray structural characterization

2004

researchProduct

Liraglutide and Renal Outcomes in Type 2 Diabetes.

2017

BACKGROUND: In a randomized, controlled trial that compared liraglutide, a glucagon-like peptide 1 analogue, with placebo in patients with type 2 diabetes and high cardiovascular risk who were receiving usual care, we found that liraglutide resulted in lower risks of the primary end point (nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes) and death. However, the long-term effects of liraglutide on renal outcomes in patients with type 2 diabetes are unknown. METHODS: We report the prespecified secondary renal outcomes of that randomized, controlled trial in which patients were assigned to receive liraglutide or placebo. The secondary renal outcome was a co…

MaleSettore MED/09 - Medicina InternaAcute Kidney Injury; Aged; Albuminuria; Creatinine; Diabetes Mellitus Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Follow-Up Studies; Glomerular Filtration Rate; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Intention to Treat Analysis; Kidney Failure Chronic; Liraglutide; Male; Middle AgedType 2 diabetes030204 cardiovascular system & hematologyurologic and male genital diseasesGLOMERULAR-FILTRATION-RATEKIDNEY-FUNCTIONDISEASElaw.inventionKidney Failurechemistry.chemical_compound0302 clinical medicineRandomized controlled trialGlucagon-Like Peptide 1lawMedicineDiabetic NephropathiesHypoglycemic Agents.Settore MED/49 - Scienze Tecniche Dietetiche ApplicateChronicRISKKidneyAcute kidney injury11 Medical And Health SciencesGeneral MedicineAcute Kidney InjuryMiddle AgedIntention to Treat Analysismedicine.anatomical_structureCreatinineTRIALFemaleliraglutide randomized controlled trial type 2 diabetes renal outcomesLife Sciences & BiomedicineType 2Glomerular Filtration Ratemedicine.drugmedicine.medical_specialtyRenal function030209 endocrinology & metabolismCARDIOVASCULAR OUTCOMESFollow-Up Studie03 medical and health sciencesMedicine General & InternalDouble-Blind MethodGeneral & Internal MedicineDiabetes mellitusInternal medicineDiabetes MellitusAlbuminuriaHumansHypoglycemic AgentsIntensive care medicineAgedCreatinineScience & Technologybusiness.industryLiraglutideMORTALITYLiraglutidemedicine.diseaseINTENSIVE GLUCOSE CONTROLINDIVIDUALSDiabetes Mellitus Type 2chemistryDiabetic NephropathieKidney Failure ChronicLEADER Steering Committee and InvestigatorsbusinessFollow-Up Studies
researchProduct

Architectures and protocols for mobile computing applications: a reconfigurable approach", Elsevier Computer Networks

2004

researchProduct

Sufentanil sublingual tablet system. From rationale of use to clinical practice

2020

The control of post-operative pain in Italy and other western countries is still suboptimal. In recent years, the Sufentanil Sublingual Tablet System (SSTS; Zalviso; AcelRx Pharmaceuticals, Redwood City, CA, USA), which is designed for patient-controlled analgesia (PCA), has entered clinical practice. SSTS enables patients to manage moderate-to-severe acute pain during the first 72 postoperative hours directly in the hospital setting. However, the role of SSTS within the current framework of options for the management of post-operative pain needs to be better established. This paper presents the position on the use of SSTS of a multidisciplinary group of Italian Experts and provides protoco…

Pain PostoperativeAdministration SublingualAnalgesia Patient-ControlledClinical practiceNeuropathic painAcute PainSSTAnalgesics OpioidSSTSsufentanilclinical practice; neuropathic pain; SSTS; surgeryPractice Guidelines as TopicHumansPain ManagementSurgeryTablets
researchProduct

Sensors

2019

biosensors
researchProduct